This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Leukemia	Preferentially expressed antigen in melanoma (PRAME)	<i>In vitro</i> and patient sample studies suggest that downregulating PRAME could help treat hematological malignancies. In several leukemia cell lines, PRAME expression was higher than that in normal hematopoietic progenitors. In chronic myeloid leukemia (CML) patients, increased PRAME mRNA correlated with greater disease progression and was associated with poor response to tyrosine kinase inhibitor therapy. Next steps could include identifying PRAME inhibitors. SciBX 2(31); doi:10.1038/scibx.2009.1207 Published online Aug. 13, 2009	Patent and licensing status unavailable	Oehler, V. <i>et al. Blood</i> ; published online June 22, 2009; doi:10.1182/blood-2008-07-170282 Contact: Vivian G. Oehler, University of Washington, Seattle, Wash. e-mail: voehler@u.washington.edu